Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
Dr. Reddy's appears to be at an inflection point where a growth portfolio built on acquisitions and heavy capital investment is colliding with structural US generics pricing pressure, as evidenced by 2027Q2 revenue declining 1.7% year-over-year to $86.6B and gross margin compressing roughly 830 basis points from 60.4%…
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue contracted 1.7% year-over-year to $86.6B in 2027Q2 while operating margin fell to 13.7% from 23.4% in 2025Q1, reflecting approximately 830 basis points of gross margin compression (60.4% to 52.1%) and negative operating leverage as SG&A held near $27-29B against a shrinking gross profit base.
Analyst consensus projects a bullish share price target of Rs 1,800-2,000 for 2026, indicating significant upside potential.
Trading at 18x P/E with a market cap of Rs 96,000 Cr, the stock presents a compelling valuation case for long-term investors.
As a global player with diverse offerings including generics and APIs, Dr. Reddy's benefits from a wide market reach and product diversification.
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 23, 2026 | $0.12+24.0% vs $0.10 | $911M+1.8% vs $895M |
Q3 2026 Jul 21, 2026 | $0.06-34.7% vs $0.09 | $836M-1.7% vs $851M |
Q2 2026 May 11, 2026 | $0.06-33.3% vs $0.09 | $786M-11.4% vs $887M |
Q1 2026 Jan 20, 2026 | $0.16+0.0% vs $0.16 | $952M+2.6% vs $928M |
Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
Semaglutide supply reloading will begin by November 2026. Base business revenue grew double digits excluding North American Lenalidomide.
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript
Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business.
Benchmark RDY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Dr. Reddy's Laboratories Limited (RDY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.98 | $12.47B | 41.64 | 8.58% | 8.46% | 7.35% | 0.6% | |
| $61.73 | $8.44B | 2128.62 | 11.05% | 2.9% | 18.07% | 7.76% | |
| $16.94 | $2.34B | -1.33 | -2.75% | -43.27% | -68.13% | 6.79% | |
| $21.88 | $6.99B | 49.78 | 8.05% | 4.62% | 82.23% | — | |
| $42.23 | $49.96B | 98.74 | 4.31% | 2.94% | 6.35% | — | |
| $20.28 | $23.62B | -38.32 | -2.98% | -4.13% | -4.24% | 2.36% |
Dr. Reddy's Laboratories Limited (RDY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when RDY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Dr. Reddy's Laboratories Limited (RDY) stock FAQ — growth, dividends, profitability & financials explained
Dr. Reddy's Laboratories Limited (RDY) reported $331.38B in revenue over the trailing twelve months. Revenue was $353.47B in fiscal year 2026. That is 3132% more than the $10.94B of fiscal year 2001.
Dr. Reddy's Laboratories Limited (RDY) revenue fell by 3.1% over the trailing twelve months, compared with the twelve months before.
Yes. Dr. Reddy's Laboratories Limited (RDY) earned $28.03B in net income over the trailing twelve months (a 8.5% net margin).
Yes. Dr. Reddy's Laboratories Limited (RDY) pays a dividend that yields 0.60% at the current price, a small yield.
Dr. Reddy's Laboratories Limited (RDY) had a return on equity (ROE) of 7.3% over the trailing twelve months. That is below the market's typical 10-15%.
Dr. Reddy's Laboratories Limited (RDY) generated $12.01B in free cash flow over the trailing twelve months.